Abstract Search

ba0007p187 | (1) | ICCBH2019

Increased prevalence of overweight and obesity and its clinical predictors in children affected by X-linked hypophosphatemia

Zhukouskaya Volha V , Rothenbuhler Anya , Colao Annamaria , Di Somma Carolina , Kamenicky Peter , Trabado Severine , Prie Dominique , Audrain Christelle , Barosi Anna , Kyheng Christele , Lambert Anne-Sophie , Linglart Agnes

Background/aim: X-linked hypophosphatemia (XLH) is a rare disease characterized by low phosphate level. Scientific evidence points to link between hypophosphatemia and obesity in general population. The aim of our longitudinal observational study was to investigate the prevalence of obesity and associated factors in a large cohort of children with XLH.Patients/methods: We selected 172 XLH-children of 520 years (113 girls/59 boys). Anthropometric pa...

0 shares

ba0007p51 | (1) | ICCBH2019

Higher dose of burosumab is needed for treatment of children with severe forms of X-linked hypophosphatemia

Zhukouskaya Volha V , Audrain Christelle , Lambert Anne-Sophie , Colao Annamaria , Kamenicky Peter , Adamsbaum Catherine , Nevoux Jerome , Chaussain Catherine , Wicart Philippe , Briot Karine , Di Rocco Federico , Trabado Severine , Prie Dominique , Rothenbuhler Anya , Linglart Agnes

Background and aim: Burosumab is a monoclonal antibody against anti-FGF23, which has been recently approved for treatment of X-linked hypophosphatemia (XLH). Beyond clinical trials, little is known about its efficacy/safety in clinical practice which is the aim of study.Patients/Methods: 39 children with XLH were switched from conventional therapy to burosumab (starting dose 0.4 mg/kg), because of following indications: non-responder to conventional ther...

0 shares

Bone Abstracts

Increased prevalence of overweight and obesity and its clinical predictors in children affected by X-linked hypophosphatemia

Higher dose of burosumab is needed for treatment of children with severe forms of X-linked hypophosphatemia

BiosciAbstracts